Belzupacap sarotalocan (AU-011)
Choroidal Melanoma (1st line)
Phase 2Active
Key Facts
About Aura Biosciences
Aura Biosciences is developing first-in-class, targeted oncology therapies designed to treat solid tumors with high precision. Its core innovation is the Virus-Like Drug Conjugate (VDC) platform, which utilizes non-infectious virus-like particles to deliver potent cytotoxic agents directly to cancer cells. The company's lead program is in Phase 2 development for choroidal melanoma, a significant unmet need, with a strategic pipeline expansion planned into urologic and other solid tumors. Aura's mission is to create a new standard of care that improves patient outcomes by sparing healthy tissue.
View full company profile